My journey with pemphigus vulgaris (PV) began at age 29 with peeling oral mucosa over the palate and gingiva, soon progressing to blisters and erosions over the abdomen and back. In 2017, a dentist suspected an autoimmune condition and mentioned ‘Pemphigus’ in the referral. However, no confirmatory testing was pursued at the initial dermatology review. I was prescribed steroids and vitamins without biopsy or immunologic workup. Symptoms temporarily improved, and I began taking steroids intermittently for oral discomfort, unaware of the condition's severity. In 2020, symptoms worsened as grief compounded my struggle. I faced multiple losses, most devastatingly my mother's death during the COVID-19 pandemic. Her prolonged hospitalization and passing left me profoundly depressed, jobless and in despair. During this period, my health became secondary to survival. Blisters spread across my scalp, gums, forearms and abdomen, persisting for months. I initially dismissed the lesions as minor. Self-management proved ineffective. A second dermatologist's topical therapies offered partial relief, but oral and scalp wounds continued. A third specialist recommended a biopsy and blood tests; however, grief and unemployment made diagnostic testing unaffordable. Eating became difficult as my gingiva eroded and bled easily. Intermittent steroid use led to weight gain and metabolic changes, prompting unsupervised discontinuation. In 2022, an anterior cruciate ligament tear required surgery, and blisters recurred at the surgical site. Over time, I recognized that stress triggered oral sores and cutaneous flares. I adapted to chronic discomfort through dietary modification, intermittent fasting and wound care. In early 2024, a fourth dermatologist clinically identified PV and prescribed low-dose steroids intermittently, but blistering persisted and worsened. In January 2025, a biopsy was performed after persistent dark-crusted lesions raised concern for malignancy, and results confirmed PV. I finally had a diagnosis, yet comprehensive evaluation and appropriate treatment were still lacking, leaving me directionless while the erosions continued. A chance encounter in March 2025 became a turning point. For the first time, I was taken seriously; my condition was assessed comprehensively, lesions and scars were thoroughly examined, and the risks of uncontrolled disease were clearly explained, giving me a sense of the bigger picture. What began as seeking relief for a solitary lesion became an understanding of the disease. For years, I had approached flares expecting only symptomatic relief. I did not anticipate this level of evaluation and explanation. As further investigations were discussed and rituximab workup initiated, the scope of the disease felt overwhelming. I had normalized years of symptoms and underestimated systemic risk. Having previously received low-dose steroids without meaningful improvement, I hesitated to restart prednisone, unaware that effective control required adequate dosing and supervised tapering. The risks, costs and intensity of therapy required time to process. I briefly considered stepping back. Yet, financial considerations were thoughtfully integrated into clinical decision-making. Investigations were streamlined, hospital packages arranged at reduced rates, and affordable laboratories identified. Persistent disease activity, structured guidance and evident concern led me to proceed despite my hesitation. In the context of my long-standing illness, I was described as ‘lucky’ that prolonged disease activity had not resulted in serious systemic consequences. Only then did I realize how much risk I had underestimated. A structured treatment plan with prednisone and rituximab was initiated after intolerance to mycophenolate mofetil. Within 4 months, antibody levels declined substantially, and the persistent abdominal lesion healed. The path remains nonlinear: Corticosteroid tapering has been accompanied by withdrawal symptoms, yet I am nearing remission, with sustained lesion control and no new blisters. Looking back, delays arose from financial barriers, incomplete diagnostic evaluation and insufficient communication of risk. Clear communication and structured partnership ultimately changed the trajectory. Being described as ‘lucky’ stays with me; not every patient may be as fortunate. Earlier clarity might have altered the course of those 8 years. Grasping the gravity of PV reframed my experience; I realized I had avoided hospitalization, aggressive immunosuppression, serious infection or significant comorbidities. This awareness, alongside gratitude for survival and for structured, compassionate, patient-centred care, continues to shape my recovery. The author wishes to acknowledge her treating physician for comprehensive care and collaborative partnership in healing. The author has nothing to report. The author declares no conflicts of interest. Not applicable. Not applicable. Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.
Saranya Subramaniyan (Fri,) studied this question.